knobs, composed of trimers of the gp120 surface protein (SU), which are anchored to the membrane by the transmembrane protein gp41 (TM) [11] . On the gp120 protein there are conformation-dependent, neutralizing epitopes that are formed in native protein but not in unfolded, denatured protein [12] . Directly beneath the viral envelope is the outer capsid membrane symmetrically built up from matrix protein (MA, p17). The conical capsid is synthesized from the inner capsid protein p24 (CA). Depending on the plane of the section, the capsid appears on electron micrographs as a cone, a ring or an ellipse ( fig. 3 ). The capsid is attached to the outer capsid membrane by its tapered pole. Inside the capsid there are 2 molecules of viral genomic RNA and several molecules of RT/RNAse H and IN that are bound to the nucleic acid [1] . The virus particle also contains the peptides cleaved off by protease during processing of the precursor proteins for gag (p55) and pol (p160) once the particle has been released from the cell during particle maturation. On completion of the budding process and of the release of the virus from the cell membrane, the maturation of HIV takes place through the processing of the gag-pol precursor proteins. The loss of the surface processes (SU trimers) as a result of shear forces after release is visible on electron micrographs [13] . Particles free of gp120 are no longer infective. Regulatory proteins: Tat accelerates the availability of viral RNA 100-fold. Tat binds to the TAR sequence of viral RNA rather than cellular RNA. In the trans position tat also activates other HIV genomes present in the cell. Tat itself is induced by tat but also by cytokines such as p65 and NF-κ B (table 1) . Rev is responsible for the splicing length of the HIV RNAs formed. This allows regulatory proteins and structural proteins to be formed at an early and late stage of the replication cycle, respectively. Nef has a negative effect on presentation of CD4 molecules at the cell surface. As a result, the membrane of the infected cell becomes deficient in CD4 and can no longer be infected by further HIV. In addition, nef enhances pathogenic action in vivo [3] . The HIV-1 nef molecule is shorter and enhances the pathogenic action to a greater extent than is the case with HIV-2. Other regulatory proteins include vif (viral infectivity factor) and vpr and vpu (viral protein r and u), which have an effect on the rate of HIV production [14, 15] . HIV-2 is identical to the mangabey viruses (smm: sooty mangabey monkey) and consists of 6 groups on the basis of phylogenetic distance, but to date has been subdivided into subtypes A to G. 2 different SIVs have been identified in the mandrill (mnd). gue: guereza colobus, gsn: greater spot-nosed monkey, drill: drill, hoesti: l'Hoest monkey, rcm: red-capped mangabey, sun: sun-tailed monkey. Each species of monkey in West Africa currently has its own HIV-like retrovirus. Gorillas do not appear to be infected with Lentiviruses. (drl), mandrills (mnd), mangabeys (smm), Sykes' monkeys (syk), colobus monkeys (gue), greater spot-nosed monkeys (gsn) and mona monkeys (mon) are nowadays also classified under HIV-2/SIV-2 [5, 16, 17] . HIV-2 is morphologically indistinguishable from HIV-1 [5] . Instead of encoding the vpu gene, the HIV-2 genome codes for a vpx. Since substantially fewer isolates have been studied, HIV-2 has so far been subdivided only into subtypes (A to G) rather than groups [4] . In view of the marked differences in the antigenicity of the viral proteins and in genome structure compared with HIV-1, diagnosis of HIV-2 necessitates its own particular reagents. To date there is no commercially available NAT (nucleic acid amplification technology) for the detection of HIV-2 nucleic acid. HIV-2 is generally less pathogenic than HIV-1 (see 1.2).
HIV-2

Infection of Human Cells
The initial stages of infection of a cell are characterized by complex protein-protein interactions. The gp120 protein of the mature HIV particle binds to the host cell's CD4 receptor. All CD4-positive cells such as T-helper cells, macrophages and astrocytes are therefore host cells for HIV. After attachment to the CD4 molecule via the C4 domain of gp120, a conformational change in CD4 and gp120 takes place, opening up an additional site for gp 120 to bind to the 'coreceptor', i.e. chemokine receptor 5 (CCR5) or chemokine receptor 4 (CXCR4 or fusin) on the cell surface [18, 19] . Binding of gp120 to CD4 and the coreceptor triggers a conformational change in gp120 and subsequently in gp41 [1] . The hydrophobic N-terminal part of gp41 is transferred to the cell surface, forms a channel and inserts itself into the plasma membrane of the target cell. Fusion of cell membrane and viral envelope is then completed.
Once the two membranes have fused, the conical capsid finds itself inside the cytoplasm. The capsid is absorbed by an endosome and its contents are released into the cytoplasm as a result of a change in pH inside the phagosome [20] . Activation of reverse transcriptase (RT) takes place in the cytoplasm. HIV RT transforms one strand of HIV RNA into DNA (complementary DNA or cDNA) and at the same time the RNA strand is destroyed by the action of RNAse H. As a result of the RNA/DNA-polymerase activity of RT, the single-stranded cDNA is converted into double-stranded DNA and at the same time the second strand of RNA is broken down by RNAse H [21] . This proviral DNA is transported via nucleopores into the cell nucleus in the form of a complex consisting of a linear strand or a ring together with integrase (IN). The integrase then inserts the proviral genome at any point in the human host cell genome. This integration process marks the completion of infection of the cell with HIV and the establishment of permanent infection. The proviral genome is either replicated with and as part of the host cell genome during cell division (latent infectionrare) or serves as an attachment region for cellular polymerases for the synthesis of viral mRNA and genomic RNA. Synthesis of viral mRNA is regulated and accelerated by tat (p14). Accumulation of HIV in a CD4 cell takes between about 30 min to 2 h, transformation of RNA into HIV DNA takes approximately 6 h and integration takes a further 6 h. After integration, the first virus particles may be produced about 12 h later, i.e. the first descendant viruses may be released after approximately 24 h. Since RT has no proof-reading activity, one nucleotide is incorporated in error during each transcription process. If HIV replication is uninhibited, 10 8 -10 9 viruses are transformed, i.e. destroyed by the immune system and repro- duced by the infected cells, per day [22, 23] . With a mutation rate of 1 in 10 4 , over time a patient will therefore develop various quasispecies. Since epitopes for neutralizing antibodies are also affected, these quasispecies continually evade the immune system and maintain HIV production [12] . Not all nucleotide exchanges result in exchange of an amino acid. Mutations involving essential regions of structural proteins or active centers of enzymes give rise to lethal mutants of HIV.
With a half-life of 2-4 days, the infected cells are destroyed in the blood of the infected person by cytotoxic HIV components or by cytotoxic T lymphocytes as part of the immune response [24, 25] . Since HIV-infected T-helper cells are also lysed and replenishment of such cells is simultaneously inhibited, gradually a deficiency in T-helper cells results. HIV products are also responsible for deficient maturation of replacement T-helper cells [3] . Some of the newly formed T-helper cells fail to function normally. After years of infection, the depletion of T-helper cells leads in almost every case to immune deficiency. Integrated HIV is able to persist latently for several years (half-life of certain target cells: 7 years) in long-lived cells such as some macrophages, astrocytes or memory T cells and to form new virus particles on activation.
Susceptibility to Inactivation and Stability of HIV Under Environmental Conditions
The stability of HIV is characterized essentially by its lipid envelope. HIV is stable at a pH between 3 and 10 [26, 27] . On exposure to heat, the virus inactivation half-life (t/2) is approximately 30 min at 56 °C, approximately 1 min at 60 °C and less than 1 sec at over 65 °C. At lower temperatures, HIV is relatively stable: t/2 at 20 °C, 4 °C and below −70 °C is approximately 9 h, several months and indefinite, respectively. At −20 °C, a slight but continuous decline in the infectivity of HIV occurs. Specimens for forensic purposes should be stored at below −20 °C. HIV is susceptible to treatment with disinfectants. Even 20% ethanol slowly reduces the infection titer and HIV is rapidly inactivated by 70% ethanol, 50% isopropanol, 4% formaldehyde and by strong detergents such as SDS, NP-40 or Triton X-100 at concentrations as low as 1% [26] . HIV particles are relatively stable on exposure to physical influences such as UV light, gamma rays or ultrasonic waves [28] . The plasma half-life (t/2) of HIV is approximately 2 days at body temperature [22] , and approximately 1 month at 4 °C. In consequence, a reduction of about 1.5 half-lives will take place in whole blood with a viral load of 100,000 particles/ml stored at 4 °C for 6 weeks, i.e. a particle count of 37,500 will remain. If one human infectious dose (1 HID) consists of approximately 500 HIV particles, even a small amount of transfused blood is sufficient to transmit infection. The ability of the HIV particle to survive in white blood cells is unclear. It is to be assumed that HIV is inactivated faster in lymphocytes than in plasma, with a half-life presumably of a few days at room temperature but several weeks at 4 °C. HIV may remains infectious for weeks in dendritic cells. In lyophilized plasma or factor concentrate in the presence of high protein concentrations, HIV remains infectious for years at room temperature.
Infection and Infectious Diseases
HIV is able to enter the body via intact mucous membranes, eczematous or damaged skin and mucous membranes and by parenteral inoculation. When transmitted through sexual contact, HIV accumulates first in dendritic cells (e.g. Langerhans' cells) or in macrophages/monocytes, and there is preferential replication of viruses (R5) using CCR-5 as a coreceptor, as has been described in mucosal M cells [29] . On exposure of blood cells to HIV, direct infection of T-helper cells may occur, resulting in transmission of R5 and X4 viruses. One human infectious dose (1 HID) is equivalent to approximately 100-1,000 HIV particles, with a higher dose required for infection via mucous membranes than via the bloodstream. The majority of new HIV infections are still transmitted sexually. Another epidemiologically relevant route is parenteral administration of drugs and also snorting of drugs with epistaxis. HIV is detectable in regional lymphatic tissue within 1-2 days of infection, in regional lymph nodes within 5-6 days and throughout the body, including the nervous system, within 10-14 days. A distinction can be made between different compartments in the body on the basis of their HIV concentrations. HIV-relevant compartments are blood, the cerebrospinal system and the genital system, such as ejaculate and vaginal secretion [30, 31] . Transmission of HIV via blood or organs, including bone, is possible from about the 5th-6th day after infection of the donor. Intrauterine transmission has been demonstrated from the 12th week of pregnancy but occurs predominantly (>90%) in the final trimester and particularly shortly before or during birth [32] . HIV is transmissible via breast milk [33] . With the onset of the humoral immune response to HIV after 3-4 weeks, the majority of infected people develop clinical symptoms [3, 34] consisting of fever, lymph node enlargement, fatigue, malaise, a rash with small, only slightly raised lesions and gastrointestinal symptoms. These symptoms are non-specific and also occur with other viral infections such as mononucleosis or influenza. Acute neuropathy is common in the acute phase. The symptoms persist for 2-4 weeks. This is usually followed by an asymptomatic phase lasting many years. At the start of the infection, virus titers of 10 5 -10 9 in the blood ( fig. 4 ) and, exceptionally, of up to 10 14 genome copies/ml are attained [34] . Donations of such blood are therefore highly infectious. During the asymptomatic phase, the viral load may drop to below <10 2 genome copies/ml. However, infected persons and their blood are still infectious even in this phase. [35, 36] . The HIV antibody screening tests authorized at present (2003) in Germany can detect HIV-specific antibodies in plasma, depending on the immune response and the test used, from about the 3rd week after infection (although usually from 4-5 weeks) or, if the immune response is delayed, from 8 weeks after infection (see 1.4.) . At the start of the infection, antibody titers are low and are directed primarily against p24 and the surface glycoproteins gp120 and gp41. Subsequently, highly avid antibodies to all HIV proteins are formed, usually within 1-3 weeks. A specific T-cell response is also induced against many of the epitopes of HIV proteins. The early immune response often involves IgM antibodies that may persist for months [3] . Some of the antibodies have neutralizing capacity if directed against gp120, gp41 or p24/p17 of the infecting virus. The principal neutralizing activity is present in antibodies directed against the V3 loop of gp120. They are strain-specific and are incapable of adequately permanently eliminating the quasispecies of HIV formed within an individual [12, 37] . Under the elimination pressure from the immune system, viruses with a variable V3 loop are selected. The V3 loop is the region of the gp120 protein in which a huge number of amino acid exchanges take place (hypervariable). Subtype differentiation is not possible by means of serological testing but can be achieved using subtype-specific amino acid sequences from the C2V3 region [4] . As immune deficiency increases, so the immune response is weakened and opportunistic infections and neoplasms develop. A characteristic feature of HIV infection is a pattern of periods of good health followed by periods of illness. As the infection progresses, the periods of illness become more common and longer-lasting [38] . Without treatment, HIV infection is always fatal. The time to occurrence of overt immunodeficiency varies from 2 to 25 years or more ( fig. 4) . The pathogens of commonly occurring opportunistic infections are Toxoplasma gondii, Cryptosporidium parvum, Pneumocystis carinii, Mycobacterium tuberculosis and atypical mycobacteria, Salmonella spp., pneumococci, the human polyomavirus JC virus, cytomegalovirus and herpes simplex virus. Typical neoplasms associated with HIV are Kaposi's sarcoma with human herpesvirus 8, non-Hodgkin's lymphomas and carcinomas of the penis and cervix caused by human papillomavirus. Where HIV infection persists for years, the marasmus that is a characteristic outward manifestation in untreated patients commences [3] . Concurrent infection with the hepatitis C virus results in faster progression of the disease [39, 40] . Some patients infected with HIV develop characteristic atrophic skin changes that have been described in the literature as seborrhoeic eczema and are a visible manifestation of the infective process. Other phenomena that are likewise detectable at an early stage are changes to the oral mucosa with gingival retraction and deep periodontal lesions as well as hairy leukoplakia on the lateral border of the tongue. The WHO and the CDC have subdivided HIV infection into stages (A1-C3) on the basis of the clinical picture and the CD4 cell count [41] . Stage A is asymptomatic, stage B denotes few symptoms through to AIDS-related complex and stage C represents AIDS-defining illness. The CD4 cell count in stages 1, 2 and 3 is over 500, between 499 and 200 and below 200 per µl blood, respectively.
Epidemiology
According to current knowledge, the spread of HIV commenced at around the time that the Second World War ended. HIV-1 was prevalent throughout Africa by the early 1970s [42] , spreading to North America (very low prevalence) in 1968 and since the mid 1980s worldwide. The prevalence of HIV differs in particular regions of the world. As is characteristic of sexually transmissible diseases, the highest prevalence is recorded in cities. In central Africa, the prevalence is as high as 30%, with both sexes roughly equally affected. Depending on the population studied, prevalences in North American cities vary between 1 and 5%, compared with approximately 0.5% in the German cities of Frankfurt/Main and Berlin (Western parts of the city). Prevalences are sometimes much lower in rural areas. In Germany, there is still a historical East/West divide. Since the driving force behind transmission of HIV is sexual contact, the only means of eliminating HIV from the human population would be by effective vaccination. However, an effective vaccine is not available and will remain unattainable for the next decade on account of the heterogeneity of the virus groups and subtypes. A DNA vaccine has likewise so far failed to make any headway in humans in terms of generating post-vaccination immunity to prevent the transmission of HIV infection [46, 47] . The only options for limiting the spread of HIV for the time being are therefore promotion of awareness of routes of transmission and use of appropriate preventive measures.
Detection Methods and Their Significance
A basic distinction can be made between two forms of detection: antibody detection and virus detection. The virus can be detected in the blood by means of NAT in cell-bound or free form about 11 days after infection.
Antibodies
The common way of detecting HIV infection is to perform antibody screening tests with subsequent confirmation of the test result. The antibody screening tests currently marketed in Germany identify antibodies that are formed against all known HIV-1 group M, N and O subtypes and against HIV-2. In addition to ELISA (enzyme-linked immunosorbent assay), particle agglutination tests are also used. ELISA tests contain antigen of HIV-1 group M (preferably HIV-1 M:B), group O and HIV-2, with particular preference presenting antigens from the constant region of gp120 and from the N-terminal portion of gp41. Particular manufacturers also include antigens from reverse transcriptase and the p24 protein [48, 49] . Depending on the immune response and the antibody titer, infection is detectable after just 3 weeks, though usually after 4-5 weeks. 8 people in the USA have so far failed to test positive for antibodies, despite having been infected for years [50] . It is not clear, however, whether detectable antibodies were present prior to the introduction of the tests. The first and second generation tests used in that study are no longer marketed in Germany.
Since the ELISA is extremely sensitive, allowing it to detect even minimal amounts of antibody, this also means that false positive results may occur. This occurs in particular if immune complexes are present in the serum and if the patient is infected with pathogens that share common epitopes with HIV or cause non-specific stimulation of the immune system. The Western blot (immunoblot) technique has been introduced in Germany as a confirmatory test [51, 52] . At present, this technique may prove less sensitive than the ELISA in the early stage of HIV infection. A set of criteria has been drawn up for evaluation of the results of the test. In Germany, it is agreed that positive detection of HIV-1 antibodies requires the presence of a band from the gag or pol region in addition to two of the glycoproteins gp160, gp120 and gp41. In the case of HIV-2, two of the glycoproteins gp130, gp105 and gp36 must be present. Normally, 5-8 Western blot bands are stained by the antibodies in an HIV-positive serum. In the early phase of the infection, only individual bands are stained, the number and intensity of the bands increasing markedly over a period of 14 days. Individual manufacturers supply blot strips with recombinant proteins, allowing simultaneous identification or differentiation of HIV-1 and HIV-2 infections. Control bands on the Western blot strips allow the test to be monitored and make it easier to read the results. Only if the aforementioned criteria for a positive Western blot apply, can a confirmed positive result be sent to the doctor re- 
Virus Detection
The p24 protein forms the inner capsid. Each virus particle contains approximately 2,000 p24 molecules [54] . Detection takes place with a combination of polyclonal and monoclonal antibodies using the sandwich ELISA technique, allowing approximately 10 5 particles to be detected with a sensitivity of 10 pg/ml. Approximately 60-80% of seroconversions take place without detectable blood concentrations of p24 antigen [55] . As the infection progresses, p24 may be present in the plasma in free or particle-bound form and high concentrations may be attained in some AIDS patients. There is no direct correlation between the particle count measured in the plasma by genome detection and the p24 antigen content, as p24 is shed by infected cells without the virus. Single antigen and combination tests, together with testing for HIV antibodies, are available for the detection of p24 protein ('4th generation' tests). A reactive p24 antigen test result likewise requires confirmation. Suitable methods are the blocking/neutralisation test or NAT. Most HIV-1 p24 antigen tests also detect HIV-2 p25 antigen, although with reduced sensitivity. Testing of blood donations for p24 protein in addition to HIV antibodies is not current practice in Germany [56] . HIV infection can be detected by means of NAT through detection of proviral DNA in lymphocytes or viral RNA genome in plasma. For testing of viral load and blood donations, the RNA is isolated from the virus particle in the plasma. Genome detection can be performed either by means of direct amplification of defined target sequences or by using probes with subsequent signal amplification techniques. Depending on the starting material and the approach, between 5 and 100 nucleic acid copies (or genome equivalents) per ml are detectable in an individual donation using NAT [36] . A WHO standard is available for quantification [57] . Commercially available NAT tests have been developed using primers that bind strictly to HIV-1 M:B nucleic acid and are therefore most sensitive for strains of HIV-1 M:B. The further remote a nucleic acid sequence is from HIV-1 M:B, the more the sensitivity of the technique is reduced. Depending on the test and the target sequence (e.g. gag or pol-IN), only HIV-1 of group M or HIV-1 of groups M, N and O is detected, respectively [58, 59] . Only 2 tests for testing blood donations using NAT are currently marketed in Germany. Since 1996, a number of blood donor centers and manufacturers of plasma derivatives have developed their own test methods (i.e. home-made or inhouse assays) for amplification of HIV. Since HIV is concentrated by ultracentrifugation, these assays are also suitable for pool testing [60] . No commercial NAT is available for detection of HIV-2. Confirmation of HIV-2 infections has therefore only been possible to date using laboratory-specific tests, e.g. PCR (polymerase chain reaction), if serological analysis is insufficient.
Commercially available HIV-NAT tests for the analysis of HIV via nucleic acid are currently as follows: LCR (ligase chain reaction), NASBA (nucleic acid sequence-based amplification), PCR (polymerase chain reaction), TMA (transcription-mediated amplification) and b-DNA SAA (branched DNA signal amplification assay).
Blood and Plasma Donors
Prevalence and Incidence in Donor Populations
Urban populations have a higher prevalence of HIV than rural ones, and female donors are less commonly infected than males [61] . The rate of HIV seroconversion amongst repeat donors in 2001 was 1 per 185,000, with a range of 1 per 130,000 to 1 per 270,000 [62] . Transmission of HIV via blood or cellular blood components such as red cell or platelet concentrates is rare, as HIV antibody tests identify infected blood donations unless they were collected during the early phase of infection before seroconversion known as the 'window period'. After testing for anti-HIV-1/-2, the residual risk of HIV transmission in recent years has been calculated from epidemiological data at around 1 in 1.5 million (range: 1:700,000 to 1:2.6 million). The introduction on May 1, 2004 of HIV-1 NAT, a procedure already performed by the majority of the blood donor services on a voluntary basis, will further reduce the risk by narrowing the window period. The low incidence of infection via this route has been achieved not simply by substantial improvement of the mandatory tests but in particular by exclusion of donors at high risk of acquiring HIV infection. Plasmapheresis donors are subject to the same selection criteria as blood donors. Plasma-derived (medicinal) products are compulsorily subject to at least 2 processes for the removal or inactivation of viruses, i.e. one viral depletion process and one inactivation process or 2 different inactivation processes. As a result, there have been no cases of transmission of HIV via plasma-derived products since 1990. According to the EuroHIV report [63] based on selected reported data, the prevalence of HIV amongst blood donors in Germany in 1999 was 1 in 100,000. Corresponding prevalences for neighbouring countries are 0.7 for England, 1.8 for France, 4.9 for Spain, 4.8 for Italy, 4.9 for Russia and 63.9 for the Ukraine. On the basis of current estimates, the HIV seroconversion rate amongst repeat donors of whole blood in Ger-many in 1999 and 2000 was 0.6 and 0.4 seroconversions per 100,000 whole blood or plasmapheresis donations, respectively [64] .
Definition of Exclusion Criteria
The grounds for excluding individuals from blood donation are laid down in the German Guidelines on Collection of Blood and Blood Components and Use of Blood Products (Hemotherapy) [65] . Donor exclusion criteria, particularly as regards the risk of transmission of HIV, are defined in detail in these guidelines. Amongst those who are excluded are people with detected HIV, HCV or HTLV-I/II infection and people who belong to or have to be assigned to a group considered to be at markedly increased risk of HBV, HCV or HIV infection compared with the general population (e.g. homosexual and bisexual men, drug abusers, male and female prostitutes, prisoners).
Donor Testing and Significance
HIV Antibody Test
Since June 2000, all tests for markers of infection marketed in Europe have been subject to the In-Vitro Diagnostics Directive [66] , which was incorporated into the German Medical Devices Law in December 2001. The tests used in Germany detect all known HIV-1 groups and subtypes and HIV-2. A reactive screening test necessitates a confirmatory test and a second blood sample is essential for verification of HIV infection where the initial test is positive (see 1.4.1). Until the result has been clarified, the donation is quarantined and, where necessary, set aside for further testing. The donor is excluded from further donation until clarification is available [53] . On the basis of the knowledge available to date, the majority of reactive screening tests in blood donors are non-specific (false positive) and are attributable not to HIV infection but to other causes, e.g. the presence of immune complexes (see 1.4.1).
Detection of HIV
By using NAT, the window period, which for antibody tests is between 3 and 6 weeks, can be reduced. Depending on the viral load, the sensitivity of the technique used and the HIV group, infection is detectable on average after just 11 days. This has to be qualified by pointing out that commercially available NAT tests are adequately sensitive to date only to HIV-1 group M viruses (see 1.4.2) . Use of NAT is nevertheless indicated, as >90% of observed seroconversions in blood donors in Germany are caused by HIV-1 M:B and all cases of transmission of HIV via cellular blood components in the past 5 years would have been identified and prevented by screening with NAT [67] .
In view of the high cost of NAT and the low incidence of infection at present amongst blood and plasma donors, the financial outlay for the additional elimination of an HIV-positive but HIV antibody-negative donation is considerable. The cost is estimated at approximately EUR 7.5 million per identified and eliminated HIV-infected donation and will be borne by the public health system in Germany with effect from May 1, 2004 in order to satisfy safety requirements [67] . Plasma and lymphocytes from a confirmed HIV-positive donation should be isolated and frozen at below -20 °C so that this material is available for clarification of whether infection has been transmitted to recipients of previous donations. The causality of HIV transmission can be established by means of nucleic acid sequence analysis at various variable genome sections [53] .
Donor Interviews
Set rules apply to donor questioning [65] . Donors must be asked about homosexual activity following a judgement by the Federal Supreme Court in 1991 [68] . The HIV-specific questions are sandwiched amongst the other questions so as not to unnecessarily intrude on the donor's privacy life. A doctor must be on hand to settle queries or ambiguities.
Donor Information and Counselling
The course of action for informing a donor of a positive HIV test result is laid down in the recommendation of the German Advisory Committee Blood [53] . HIV-infected donors are referred to their general practitioner or a specialist centre for subsequent management and the general practitioner is informed of the result of the testing. The donor is informed in writing by the blood donor service that he/she is unsuitable as a donor of blood, plasma or organs for the rest of his/her life. The donor must be made aware that the infection can be transmitted by unprotected sexual intercourse. Female donors of child-bearing age should be informed of the risk of motherto-child transmission. The symptoms of HIV infection can be controlled for at least a few years with appropriate antiretroviral chemotherapy (see also 3.4) and this should be drawn to the attention of HIV-infected donors. Identification of the possible source of the donor's infection is of general epidemiological interest. An attempt should be made to elicit this information in conversation with the donor with the primary purpose of preventing further spread of the infection. In accordance with § 7 of the Infection Control Law [69] , reporting of newly detected cases of HIV, without identifying the patient by name, is mandatory.
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Recipients
Prevalence and Incidence of Blood-Associated Infections and Infectious Diseases in Recipient Populations
Prior to the introduction of obligatory testing for HIV antibodies between May and October 1985, approximately 200 recipients of transfusions had been infected by blood donations [70] . Approximately 1,380 hemophiliacs had become infected with HIV by the mid 1980s through use of non-inactivated clotting products. With the introduction of antibody screening tests and inactivation methods for HIV and hepatitis viruses during the manufacture of plasma products, the incidence of such transmission decreased substantially. Since 1990, there have been no further cases of transmission of HIV via clotting products. On the basis of reports received by the Paul Ehrlich Institute, a total of 4 cases of transmission of HIV via cellular blood components have occurred in the past 5 years.
As in the case of HIV-infected donors, lymphocytes and plasma from HIV-infected recipients should likewise be set aside [53] so that the source of the infection can possibly be established using molecular methods.
Immune Status (Resistance, Existing Immunity, Immune Response, Age, Exogenous Factors)
There is no protective immunity against HIV. Someone already infected with HIV-1 M:B can become superinfected with another HIV-1 M:B strain at any time [37] . HIV-2 infection does not confer protection against infection with HIV-1 and vice versa [71] . The extent to which mutations (∆32 deletion, mutations) in the chemocine receptor 5 (CCR5) gene inhibit parenteral infection is unclear [29] . Approximately 1% of the population in Germany carry this mutation and it is therefore epidemiologically irrelevant. Epidemiological studies indicate that a higher HIV dose may be necessary for sexual transmission to a person who is homozygous for the deletion in the CCR5 gene. During the first few years, the course of the disease in people who are heterozygous for the ∆32 mutations would appear to be slowed. The older the patient is at the time of infection, the higher is the risk of premature development of an immune deficiency [72, 73] .
Severity and Course of the Disease
Infection with HIV is always chronic and ultimately fatal. The symptoms can at best be prevented or suppressed for some years with antiretroviral therapy. Without treatment, AIDSdefining symptoms occur on average after about 10 years (range: 2-25 years). HIV-2-induced AIDS becomes manifest on average after 15 years. With antiretroviral chemotherapy, it is possible to prolong the period with few, if any, symptoms for many years.
Therapy and Prophylaxis
Considerable progress in the treatment of HIV infection has been made since 1987. Therapy involves use of medicinal products with different spectra of action (nucleoside (NRTI), nucleotide (NtRTI) and non-nucleoside (NNRTI) reverse transcriptase inhibitors, combined with protease inhibitors (PRI) or additionally a fusion inhibitor), as summarized in table 2. Once antiretroviral agents have been administered and have taken effect, immune system function may recover and the clinical symptoms may consequently partly or fully resolve. Elimination of HIV from the body of an infected person by therapy is not possible. Combination therapy with NRTIs and boosted PRIs is reported to delay the development of resistance of HIV for as long as possible. The best long-term results are attainable if treatment is commenced before the onset of marked immunodeficiency, i.e. when the CD4 count is around 500/µl and the viral load is between 10,000 and 20,000 genome equivalents/ml [73] . In individual cases, treatment may be indicated soon after infection, i.e. before or at the start of seroconversion. Even when therapy is commenced at such an early stage, it must be borne in mind that drug-resistant viruses are already being transmitted [75] . Side effects: Even though triple combination therapy suppresses HIV replication very well in some cases, the treatment [74] .
is associated with side effects that may considerably impair quality of life. Furthermore, antiretroviral agents sometimes interact with each other and with other medication, necessitating specialist knowledge on the part of the prescriber. Optimum therapy is currently available only for infections with HIV-1 M:B and the group M viruses. It must be appreciated that individual HIV-1 group M subtypes, HIV-1 group O and HIV-2 are already exhibiting natural resistance to NNRTIs and PRIs. In individual cases and particularly in seroconverters from high-risk groups, it is advisable to test for HIV resistance before commencing therapy [75] . New drugs need to be developed to counter the increasing development of resistance. Clinical trials are currently in progress in particular with chemotherapeutic agents that inhibit the initial steps of the infection process (fusion inhibitors and coreceptor antagonists) [74] or that target other viral functions, such as integrase (integrase inhibitors) [76] . Antiretroviral combination therapy may result in some cases in an improvement in the symptoms of immunodeficiency and a return to an almost normal state of health. The improvement in quality of life may nevertheless be limited by the side effects of the drugs. These typically include lipodystrophy, particularly breakdown of the buccal fat pad and the subcutaneous fat of the extremities, as well as accumulation of umbilical and nuchal fat. Common side effects are diarrhea, sleep disturbances, poor concentration, failure to gain weight despite adequate food intake, diabetes, anemia and neurological disorders [3] . Adjuvant immunotherapy with interleukins, e.g. interleukin-2, or therapeutic vaccines so far has not resulted in visible clinical success [77, 78] .
Transmissibility
HIV is transmitted via body fluids such as blood, plasma or serum, genital secretions and transplanted organs such as kidney, bone, cornea, etc. Transmission via artificial insemination has occurred. Transmission via saliva and bites has been reported in isolated instances. Exposure of fresh open skin lesions to fresh blood may lead to transmission of HIV in exceptional circumstances. HIV is not transmitted via aerosols, social contact, bites of arthropods, food, or water.
Frequency of Administration, Type and Amount of Blood Products
Transmission of HIV between 1979 and 1989 was essentially via factor VIII and factor IX (PPSB) products. Antithrombin III (AT-III) and i.m. immunoglobulin did not transmit HIV even prior to the introduction of special virus depletion and inactivation steps. No cases of HIV transmission have occurred as a result of administration of albumin.
In the past 12 years, only isolated instances of transmission of HIV via blood components have been reported in Germany. If a human infectious dose (1 HID corresponds to approximately 100-1,000 HIV particles) is present in the administered volume of blood components, HIV is transmitted. There are indications that infection with HIV can be prevented in isolated instances if therapy is commenced immediately [79] . Plasma components are free of the risk of HIV transmission as a result of donor selection, donor testing and use of physical and chemical steps for the depletion and inactivation of viruses during manufacture of the products. In the case of transfusions of red cell, granulocyte or platelet products derived from blood collected prior to HIV antibody seroconversion, there is a residual risk of HIV transmission which is currently approximately 1 in 1.5 million (see 2.1). Cases of transmission of HIV via fresh-frozen plasma (FFP) have not been reported since the introduction of mandatory quarantining [80] .
Blood Products
Infectious Load of the Starting Material and Test Methods
As a result of donor selection, quarantine procedures and testing of donors for HIV antibodies, the theoretical risk of contamination of plasma pools used for the manufacture of plasma products is nowadays very low (see also details of prevalence and incidence of HIV amongst blood donors in 1.3 and 2.1). This residual risk is further reduced by use of NAT testing of pools and individual donations.
Methods for Removal and Inactivation of the Infectious Agent
The manufacture and purification of individual proteins from plasma is not sufficient as a means of completely removing HIV. Since the routine adoption of validated virus removal and inactivation procedures for the manufacture of plasma products, no further cases of transmission of HIV via plasma products have been reported. Removal/depletion, including inactivation, is therefore efficient also in practice. Use of both processes must continue in the future on account of the ongoing possibility of contamination with HIV or other transfusion-relevant viruses. HIV is unstable on exposure to heat and detergents (1.1.4). It can be inactivated using the solvent/detergent (SD) method [81] , reagents such as tri(n-butyl)phosphate (TNBP) and Triton X-100 or polysorbate 80. HIV is reliably inactivated by pasteurization at 60 °C for 10 h in a liquid medium. Exposure of lyophilized products to heat (e.g. at 80 °C for 72 h with corresponding residual moisture) results in HIV inactivation. Such steps are incorporated into the manufacture of plasma products. Since the plasma products are also unstable on exposure to heat, the inactivation steps must be performed under appropriate, validated conditions. The aim is optimum preservation of the biological activity and natural conformation of the product and, at the same time, inactivation of potentially contaminating viruses [82, 83] . Irradiation with UV light and treatment with β-propiolactone [28] are effective at a low protein concentration, e.g. in the inactivation of purified immunoglobulin.
Other inactivation methods such as use of light and methylene blue, riboflavine, and psoralen require further evaluation as regards efficacy, immunogenicity of the denatured proteins, mutagenicity and carcinogenicity, as these pathogen-inactivating substances also target genetic material [84] [85] [86] [87] [88] [89] .
Feasibility and Validation of Procedures for Removal/ Inactivation of the Infectious Agent
The manufacturer of a plasma product such as clotting factors, immunoglobulins, albumin, etc., must prove in the regulatory documentation that the methods used during manufacture reliably inactivate HIV. This must include compliance with the rules for validation of such methods laid down by the European regulatory authority [90] . It is also necessary to prove with experimental data that the differences that occur during manufacture of the individual product batches (such as process conditions or composition of intermediates) do not interfere with HIV inactivation. The required combination of at least 2 manufacturing steps that effectively inactivate/remove HIV guarantees a uniformly high level of product safety from batch to batch. Validation of the different inactivation and removal steps has to be performed with HIV, which can be grown at high titers in cell cultures. Since HIV-1 and HIV-2 can be considered physically and chemically identical, it is sufficient to use HIV-1 for validation of a method. SIV, which is less pathogenic in humans than HIV, is presently unacceptable as a model virus, as differences between HIV and SIV cannot be ruled out.
Assessment
According to current knowledge, HIV-1 has been transmitted via blood and blood products in Germany since 1979. With the introduction of antibody testing of blood and plasma donations in 1985, transmission of infections via blood, blood components and plasma products has been dramatically reduced. The residual risk of transmission of HIV with red cell, granulocyte and platelet concentrates, which are not currently subject to virus inactivation/removal procedures, is already very low at approximately 1 per 1.5 million donations. In the case of fresh-frozen plasma, which is subject to quarantine rules, there have been no known cases of transmission of HIV. Plasma products that have correctly undergone virus inactivation/removal procedures during manufacture currently pose no residual risk of HIV transmission. The introduction of NAT for HIV-1 genome will bring about a further reduction in the residual risks for cellular blood components. The window period for antibody formation of approximately 21-45 days will be reduced as a result to approximately 11 days, as even incipient HIV infection is detectable with NAT. The spread of HIV amongst the German population in around 1978 is an example of how rapidly an established level of safety can collapse even in the blood services sector. The measures introduced for donor selection, inactivation of plasma products and selective use of blood and blood components should prevent a repeat of transmission of an enveloped virus on such a scale in the future. 
